Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
| Status: | Completed |
|---|---|
| Conditions: | Skin Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/25/2018 |
| Start Date: | May 2002 |
| End Date: | November 2005 |
Phase 2 Trial of Karenitecin (BNP1350) in Patients With Malignant Melanoma
The purpose of this study is to evaluate the safety and efficacy of Karenitecin (BNP1350) as
a treatment for Malignant Melanoma.
a treatment for Malignant Melanoma.
- Confirmed diagnosis of malignant melanoma
- Measurable disease
- Granulocytes ≥1,500/µl, Platelets ≥100,000/µl, Creatinine ≤ULN, Bilirubin ≤1.5 mg/dl,
AST ≤2.5 x ULN
- No prior treatment with other camptothecin drug.
- ≥ 21 days since completion of prior chemotherapy, ≥6 weeks since prior Mitomycin-C
- ECOG Performance Status 0-1
- Negative pregnancy test for female patients
We found this trial at
1
site
Click here to add this to my saved trials
